A Randomized, Double-Blind, Placebo-Controlled Trial of Doxazosin for Nightmares, Sleep Disturbance, and Non-Nightmare Clinical Symptoms in Post-Traumatic Stress
Latest Information Update: 07 May 2024
At a glance
- Drugs Doxazosin (Primary)
- Indications Post-traumatic stress disorders
- Focus Therapeutic Use
- 29 Apr 2024 Planned End Date changed from 1 Jun 2023 to 1 Jun 2024.
- 29 Apr 2024 Planned primary completion date changed from 1 Jun 2023 to 1 Jun 2024.
- 29 Apr 2024 Status changed from recruiting to active, no longer recruiting.